Status:
COMPLETED
Ivermectin and Human Immunity
Lead Sponsor:
University of Georgia
Conditions:
Ivermectin
Eligibility:
All Genders
18-65 years
Phase:
EARLY_PHASE1
Brief Summary
We hypothesize that ivermectin, a drug used to treat parasitic worm infections, interacts with the human innate immune system and that this contributes to its anti-parasitic effects. Participants will...
Detailed Description
Subjects will visit the University of Georgia (UGA) Clinical \& Translation Research Unit (CTRU) twice on consecutive days and blood will be drawn from them. On the first occasion they will be weighed...
Eligibility Criteria
Inclusion
- Weight over 110 pounds and under 185 pounds
Exclusion
- Pregnancy or nursing mothers.
- Immunosuppressed individuals.
- Hypersensitivity to ivermectin, cellulose, starch, magnesium stearate, butylated hydroxyanisole, or citric acid powder (inert ingredients of Stromectol).
- Recent (last 3 years) travel to West or Central Africa, or any other country where onchocerciasis is present
- Hepatitis/HIV
- Currently taking warfarin
- Lactose intolerance (Lactose present in placebo)
- Currently taking Steroid medications (inhaled, oral or injection)
- Currently taking Barbiturates, Benzodiazepines such as Xanax or Klonopin, Valproic acid (Lithium), Calcium channel blockers, Statins (cholesterol medication)
- Liver or renal dysfunction
Key Trial Info
Start Date :
February 12 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2018
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT03459794
Start Date
February 12 2018
End Date
November 30 2018
Last Update
July 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Georgia
Athens, Georgia, United States, 30602